GleamWall
中文EN

BBLG Bone Biologics Corp

Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1419554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY28.0%
TTM EPS YoY57.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-47.5%
ROA-44.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets7.5%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$1.06M$2.13M
SG&A expense$2.17M$2.09M
Operating income-$3.23M-$4.22M
Net income-$3.11M-$4.11M
EPS (basic)-2.65-28.96
EPS (diluted)-2.65-28.96
Weighted avg. shares (diluted)1.17M252,960
Balance sheet
Cash & equivalents$5.33M$3.33M
Current assets$5.80M$3.86M
Total assets$5.80M$3.86M
Current liabilities$418,587$377,712
Total liabilities$418,587$377,712
Shareholders' equity$5.38M$3.48M
Shares outstanding1.80M492,417
Cash flow statement
Operating cash flow-$2.69M-$4.12M
Financing cash flow$4.70M$4.42M
Stock-based compensation$256,358$188,819

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.